Literature DB >> 22949048

Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.

Aron Goldhirsch, Richard D Gelber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22949048     DOI： 10.1038/nrclinonc.2012.155

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

Authors:  Jonas Bergh; Per-Ebbe Jönsson; Elisabet Kerstin Lidbrink; Maureen Trudeau; Wolfgang Eiermann; Daniel Brattström; Justin P O Lindemann; Fredrik Wiklund; Roger Henriksson
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

3.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Authors:  Angelo Di Leo; Guy Jerusalem; Lubos Petruzelka; Roberto Torres; Igor N Bondarenko; Rustem Khasanov; Didier Verhoeven; José L Pedrini; Iya Smirnova; Mikhail R Lichinitser; Kelly Pendergrass; Sally Garnett; Justin P O Lindemann; Francisco Sapunar; Miguel Martin
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

4.  Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.

Authors:  Luciana F Macedo; Gauri J Sabnis; Olga G Goloubeva; Angela Brodie
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Authors:  Thomas Bachelot; Céline Bourgier; Claire Cropet; Isabelle Ray-Coquard; Jean-Marc Ferrero; Gilles Freyer; Sophie Abadie-Lacourtoisie; Jean-Christophe Eymard; Marc Debled; Dominique Spaëth; Eric Legouffe; Djelila Allouache; Claude El Kouri; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

6.  Combination anastrozole and fulvestrant in metastatic breast cancer.

Authors:  Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2012-08-02       Impact factor: 91.245

7.  Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors:  A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2011-06-27       Impact factor: 32.976
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.